SNF Nostos


Barry S. Coller

Vice President for Medical Affairs
The Rockefeller University

Barry S. Coller received his BA degree from Columbia College and his MD from New York University School of Medicine. He completed his residency in internal medicine at Bellevue Hospital in New York City and advanced training in hematology and clinical pathology at the National Institutes of Health. He was a member of the faculty at Stony Brook from 1976-1993 and served as the Head of the Hematology Division and Clinical Chief of the University Hospital Hematology Laboratory. He was awarded the title of Distinguished Service Professor of Medicine and Pathology at Stony Brook in 1993. Dr. Coller served as the Murray M. Rosenberg Professor of Medicine and Chairman of the Samuel Bronfman Department of Medicine at Mount Sinai School of Medicine in New York City from 1993-2001. He currently serves as the David Rockefeller Professor of Medicine; Head, Allen and Frances Adler Laboratory of Blood and Vascular Biology; Physician-in-Chief of The Rockefeller University Hospital; and Vice President for Medical Affairs at The Rockefeller University. He also serves as the founding Director of the Rockefeller University Center for Clinical and Translational Science and the Principal Investigator of the University’s Clinical and Translational Science Award (CTSA) from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health. Dr. Coller served as President of the American Society of Hematology and as founding President of the Society for Clinical and Translational Science. Dr. Coller’s research interests have focused on hemostasis and thrombosis, in particular platelet physiology. He developed a monoclonal antibody that inhibits platelet function and a derivative of that antibody (abciximab; ReoPro) was approved for human use by the FDA in 1994; abciximab has wide clinical use to prevent complications of percutaneous coronary interventions such as angioplasty and stent insertion for heart attacks and more than 5 million patients have been treated with abciximab. Dr. Coller serves as Co-Chair of the NCATS CTSA Steering Committee and was a member of the National Academy of Sciences Human Genome Editing Committee in 2015-2017. He is a member of Phi Beta Kappa, Alpha Omega Alpha, the National Academy of Medicine, and the National Academy of Sciences. He is a Fellow of the American Academy of Arts & Sciences. His honors include an American Heart Association National Research Achievement Award, the Henry M. Stratton Medal from the American Society of Hematology, and the Warren Alpert Foundation Award from Harvard University.